Leber’s Hereditary Optic Neuropathy (LHON) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Leber's hereditary optic neuropathy (LHON) is characterized by rapid bilateral loss of central vision. Primarily male patients are affected in early adult life. Optic atrophy commonly appears within 3 months after the onset of the disease. Relatives in the maternal line often show peripapillary microangiopathy typical for LHON. In most cases, symptoms begin with one eye first, followed a few weeks later by visual failure in the other eye. Extremely rarely there may be neurologic abnormalities, such as peripheral neuropathy, postural tremor, nonspecific myopathy, and movement disorders. LHON is caused by mutations in mitochondrial DNA and is strictly transmitted by maternal inheritance. The acute phase of LHON is characterized by a loss of central vision, including blurring and reduced perception of color. Individuals usually lose vision in one eye first and then lose vision in the other eye after two to three months. The atrophic phase is characterized by bilateral optic atrophy, resulting in lifelong blindness.

According to Thelansis disease area data modeling the prevalence of LHON is ranges between 1to 1.4 cases per 45,000, while the incidence of LHON is 1.2 in 1,000,000 population.

The competitive landscape of Leber’s Hereditary Optic Neuropathy (LHON) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Leber’s Hereditary Optic Neuropathy (LHON) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Leber’s Hereditary Optic Neuropathy (LHON) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Leber’s Hereditary Optic Neuropathy (LHON) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          elamipretide (MTP-131) Stealth BioTherapeutics Inc.      Phase 2

2          GS010  GenSight Biologics        Phase 3

3          Visomitin           Mitotech SA      Phase 1/2

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033